Reference | </br>1:The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53 – p21 – Rb – E2F1 Cascade in the p53wildtype Neuroendocrine Tumor Cell Line GOT1. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, Jeay S, Wuerthner JU, Aristizabal Prada ET, Spöttl G, Maurer J, Auernhammer CJ.Neuroendocrinology. 2016 Nov 21. [Epub ahead of print] No abstract available. PMID: 27871087 </br>2:Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D.Elife. 2016 Nov 17;5. pii: e19317. doi: 10.7554/eLife.19317. No abstract available. PMID: 27852439 Free PMC Article</br>3:Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, Chène P, Jeay S, Gessier F.J Med Chem. 2015 Aug 27;58(16):6348-58. doi: 10.1021/acs.jmedchem.5b00810. Epub 2015 Aug 5. PMID: 26181851 </br>4:A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, Kallen J, Furet P, Gessier F, Holzer P, Masuya K, Würthner J, Halilovic E, Hofmann F, Sellers WR, Graus Porta D.Elife. 2015 May 12;4. doi: 10.7554/eLife.06498. Erratum in: Elife. 2016 Nov 17;5:. PMID: 25965177 Free PMC Article
|